Abstract
Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels
| Original language | English |
|---|---|
| Article number | e40362 |
| Journal | PLoS One |
| Volume | 7 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 30 2012 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients : Clues for the pathogenesis. / Ferraccioli, Gianfranco; Tolusso, Barbara; Bobbio-Pallavicini, Francesca; Gremese, Elisa; Ravagnani, Viviana; Benucci, Maurizio; Podestà, Edoardo; Atzeni, Fabiola; Mannocci, Alice; Biasi, Domenico; Manfredi, Mariangela; Sarzi-Puttini, Piercarlo; Laganà, Bruno; Montecucco, Carlomaurizio.
In: PLoS One, Vol. 7, No. 7, e40362, 30.07.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients
T2 - Clues for the pathogenesis
AU - Ferraccioli, Gianfranco
AU - Tolusso, Barbara
AU - Bobbio-Pallavicini, Francesca
AU - Gremese, Elisa
AU - Ravagnani, Viviana
AU - Benucci, Maurizio
AU - Podestà, Edoardo
AU - Atzeni, Fabiola
AU - Mannocci, Alice
AU - Biasi, Domenico
AU - Manfredi, Mariangela
AU - Sarzi-Puttini, Piercarlo
AU - Laganà, Bruno
AU - Montecucco, Carlomaurizio
PY - 2012/7/30
Y1 - 2012/7/30
N2 - Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels
AB - Objective: To find out whether a high number of auto-antibodies can increase the probability of a "good-EULAR response" and to identify the possible biomarkers of response in seropositive rheumatoid arthritis (RA) patients undergoing the B cell depletion therapy (BCDT). Patients and Methods: One hundred and thirty-eight patients with long standing RA (LSRA), 75% non or poorly responsive to one or more TNFα blockers, all seropositive for at least one autoantibody (AAB) (RF-IgM, RF-IgA, RF-IgG, anti-MCV, ACPA-IgG, ACPA-IgA, ACPA-IgM) received one full course of BCDT. The major outcomes (moderate or good-EULAR response) were assessed after 6 months of therapy. The IL6 and BAFF levels were also determined. Results: At a 6-month follow-up, 33 (23.9%) of the RA patients achieved a good EULAR response. Having up to 5-AABs positivity increased the chances for treatment response. After a logistic regression analysis, however, only 4 baseline factors arose as associated with a good-EULAR response: no steroid therapy (OR = 6.25), a lymphocyte count 52.1 IU/ml (OR = 8.37) and BAFF levels
UR - http://www.scopus.com/inward/record.url?scp=84864467675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864467675&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0040362
DO - 10.1371/journal.pone.0040362
M3 - Article
C2 - 22859946
AN - SCOPUS:84864467675
VL - 7
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 7
M1 - e40362
ER -